The research, using information from the QResearch database - a joint not-for-profit project from the University of Nottingham and EMIS Health – compared diabetes drugs, particularly newer drugs (thiazolidinediones and gliptins) in their ability to control blood sugar levels and prevent serious complications.
Professors Julia Hippisley-Cox and Carol Coupland at the University of Nottingham used the QResearch database of anonymised patient records to analyse records of 469,688 adult patients with Type 2 diabetes from 2007-2015.
They found clinically important differences between different drugs (alone and in combination) and risk of five key outcomes – blindness, amputation, severe kidney failure, high blood sugar and low blood sugar.
Read the story in full on the EMIS Health website.
Read the full research paper.
